BioLoomics

BioLoomics

Pioneering Engineered Antibodies For Better ADCs and Cancer Therapies

Founded 2019

Boulder, United States 16 employees Seed Total: $10.12M Biotechnology, Health Care +1

BioLoomics is a pioneering preclinical stage biotechnology company founded in 2019 and based in the United States. The company's slogan, "Pioneering Target Degrading Antibodies Using Directed Evolution in Human Cells," reflects its core mission of leveraging directed evolution of antibodies in human cells to create target degrading antibodies. BioLoomics' proprietary technology harnesses single-cell bioassay engineering, robotics, and ML, emphasizing its focus on synbio, directed evolution, and antibodies. In a recent milestone, BioLoomics secured a significant $8.70M in a Seed Round investment on 19 September 2023. The funding round saw participation from a diverse group of high-profile investors, including Horizons Ventures, Innovation Endeavors, Boom Capital Ventures, BoxOne Ventures, Hummingbird Ventures, TechU Ventures, GC&H Investments, Nomads Ventures, and Viswa Colluru. This investment is indicative of the industry's growing interest in the company's approach and potential within the Biotechnology and Health Care sectors. BioLoomics' innovative and interdisciplinary approach to antibody development, coupled with its recent infusion of capital from a syndicate of prominent investors, positions the company for further growth and advancement within the biotechnology landscape.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	$8.70M	9	Horizons Ventures, Innovation Endeavors +7	19 Sep 2023
Pre Seed Round	$575.00K	-		11 May 2021
Grant	$240.00K	-		21 Nov 2019
Seed Round	$600.00K	-		30 May 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

$8.70M

Horizons Ventures, Innovation Endeavors +7

19 Sep 2023

Pre Seed Round

$575.00K

11 May 2021

Grant

$240.00K

21 Nov 2019

Seed Round

$600.00K

30 May 2019

FAQ About BioLoomics

Pioneering Engineered Antibodies For Better ADCs and Cancer Therapies

BioLoomics was founded in 2019.

BioLoomics is headquartered in Boulder, United States.

BioLoomics operates in Biotechnology, Health Care and Autonomous and Sensor Tech. Its work centres on directed evolution, antibodies, single-cell bioassay and robotics.

BioLoomics has approximately 16 employees.

BioLoomics has completed 4 funding rounds, raising a total of $10.12M. The latest funding stage is Seed.

Top alternatives and competitors to BioLoomics include Dima Biotechnology, Acepodia, GO Therapeutics, Trellis Bioscience Inc., Berkeley Lights. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

BioLoomics and Dima Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About BioLoomics

Funding Rounds & Investors (4)

BioLoomics Alternatives & Competitors

FAQ About BioLoomics